



an Open Access Journal by MDPI

## Hereditary Metabolic Diseases: The Biological Clock and Innovative Therapies

Guest Editors:

**Prof. Dr. Gianluigi Mazzocchi**

Department of Medical Sciences,  
Division of Internal Medicine and  
Chronobiology Laboratory,  
Fondazione IRCCS Casa Sollievo  
della Sofferenza, 71013 San  
Giovanni Rotondo, Italy

**Prof. Dr. Roberto Tarquini**

Division of Internal Medicine I,  
San Giuseppe Hospital, 50053  
Empoli, Italy

Deadline for manuscript  
submissions:

**closed (31 January 2024)**

### Message from the Guest Editors

Dear Colleagues,

Hereditary metabolic diseases constitute a variety of congenital pathologies caused by genetic defects that have an impact on metabolism, especially within the cells of the liver. There are hundreds of hereditary metabolic diseases, caused by genetic defects of various kinds. New medical treatment strategies and advanced therapies represent an important and urgent need. Advanced therapies are innovative treatment tools and strategies that offer new opportunities for the treatment of inherited metabolic diseases for which conventional treatments have proved inadequate. Advanced therapies contain genetic material, stem cells, or tissue-engineered modified cells/tissues to be used to repair, regenerate, or replace human tissue. These therapies offer the possibility of personalizing the treatment and reducing the side effects.

For this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: hereditary metabolic diseases, the biological clock, innovative therapies, stem-cell therapy, regenerative medicine, and cell/tissue engineering.

We look forward to receiving your contributions.



[mdpi.com/si/132643](https://mdpi.com/si/132643)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI